TIMP-1 EXPRESSION BY NORMAL LYMPHOCYTES AND IN LYMPHOID NEOPLASMS
正常淋巴细胞和淋巴肿瘤中的 TIMP-1 表达
基本信息
- 批准号:3752120
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:B lymphocyte Burkitt's lymphoma CD antigens Retroviridae T lymphocyte apoptosis athymic mouse cold temperature enzyme mechanism gene expression human tissue metalloenzyme neoplasm /cancer genetics neoplasm /cancer invasiveness neoplastic growth tissue /cell culture tissue inhibitor of metalloproteinases transfection
项目摘要
We have studied the expression of TIMP-1 in a series of Burkitt cell
lines. Burkitt's lymphoma, common in AIDS patients, is an aggressive
neoplasm without effective therapy in the immunocompromised host.
Northern blot analysis reveals that TIMP-1 is expressed at the RNA level
by 4 out of 9 lines studied. Cell lines from both African and American
Burkitt's express TIMP-1, as do Burkitt cells with t(8;14) and t(8;22)
translocations. All of the Burkitt cell lines studied with demonstrable
TIMP-1 RNA transcripts secreted TIMP-1 protein (as determined by Western
blot analysis) into the culture media. TIMP-1 expression does not
correlate with EBV involvement, p53 mutations, or levels of myc expression
in these lines. The cell lines that express TIMP-1 have a higher rate of
cell proliferation in vitro compared to those negative for TIMP-1
transcripts. We are purifying TIMP-1 protein and intend to study the
effect of TIMP-1 on growth kinetics in vitro. The TIMP-1 expressing
Burkitt cell lines are also more tumorigenic and invasive in the nude
mouse model. Invasion of skin and nerve is seen in only in TIMP-1
expressing lines. This aggressive behavior may be due to high growth
rate, enhanced invasive behavior or a combination of the two. We are
currently studying four cell lines (two expressing TIMP-1 and two
negative) in invasion assays to assess invasive behavior. We plan to
infect TIMP-1 negative cell lines with a retroviral construct containing
TIMP-1 to cause TIMP-1 expression in order to study the effect of TIMP-1
on growth rate and invasiveness.
In four of the Burkitt cell lines studied, Gelatinase B activity can be
demonstrated by zymogram but not by Northern blot analysis. TIMP-1 and
Gelatinase B coexpression is seen in only one cell line, with very low
enzyme expression noted. The remainder of the Gelatinase B activity was
demonstrated in TIMP-1 negative cell lines. Gelatinase A expression was
not observed in any Burkitt cell lines. If TIMP-1 functions in Burkitt's
lymphoma by blocking gelatinase activity, we would have expected to be
able to demonstrate gelatinase expression by Northern blot or zymogram in
the TIMP-1 positive cell lines. As gelatinase expression may occur in
these cells in response to the extracellular matrix, we are studying the
expression of Gelatinase A and Gelatinase B in Burkitt cell tumors grown
in nude mice.
我们研究了TIMP-1在Burkitt细胞中的表达,
线伯基特淋巴瘤,常见于艾滋病患者,是一种侵袭性淋巴瘤。
免疫功能低下的宿主中没有有效治疗的肿瘤。
北方印迹分析显示TIMP-1在RNA水平表达
研究的9条线中有4条。 非洲和美洲的细胞系
Burkitt's表达TIMP-1,t(8;14)和t(8;22)的Burkitt细胞也表达TIMP-1
易位 研究的所有Burkitt细胞系都具有可证明的
TIMP-1 RNA转录物分泌TIMP-1蛋白(如通过Western印迹法测定)。
印迹分析)到培养基中。 TIMP-1表达不
与EBV感染、p53突变或myc表达水平相关
在这些线。 表达TIMP-1的细胞系具有更高的凋亡率。
与TIMP-1阴性的细胞相比,体外细胞增殖
成绩单 我们正在纯化TIMP-1蛋白,并打算研究TIMP-1蛋白的作用。
TIMP-1对体外生长动力学的影响。 TIMP-1表达
Burkitt细胞系在裸细胞中也更具致瘤性和侵袭性
小鼠模型 仅在TIMP-1中可见皮肤和神经浸润
表达线条。 这种攻击性行为可能是由于高增长
率,增强的侵入行为或两者的组合。 我们
目前正在研究四种细胞系(两种表达TIMP-1,两种表达TIMP-2),
阴性)以评估侵袭行为。 我们计划
用逆转录病毒构建体感染TIMP-1阴性细胞系,所述构建体含有
为了研究TIMP-1的作用,
生长速度和侵袭性。
在所研究的四种伯基特细胞系中,明胶酶B活性可以被检测到。
通过酶谱而不是通过北方印迹分析证实。 TIMP-1和
明胶酶B共表达仅见于一个细胞系,
酶的表达。 明胶酶B活性的其余部分为
在TIMP-1阴性细胞系中证实。 明胶酶A表达为
在任何伯基特细胞系中均未观察到。 如果TIMP-1在Burkitt's
淋巴瘤通过阻断明胶酶活性,我们本来预计
能够通过北方印迹或酶谱证明明胶酶表达,
TIMP-1阳性细胞株。 由于明胶酶表达可能发生在
这些细胞对细胞外基质的反应,我们正在研究
明胶酶A和明胶酶B在Burkitt细胞瘤中的表达
在裸鼠中。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
M STETLER-STEVENSON其他文献
M STETLER-STEVENSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('M STETLER-STEVENSON', 18)}}的其他基金
TIMP EXPRESSION BY NORMAL LYMPHOCYTES AND IN LYMPHOID NEOPLASMS
正常淋巴细胞和淋巴肿瘤中的 TIMP 表达
- 批准号:
5201033 - 财政年份:
- 资助金额:
-- - 项目类别:
EXPRESSION OF ONCOGENES IN LYMPHOPROLIFERATIVE DISORDERS
淋巴增殖性疾病中癌基因的表达
- 批准号:
3813436 - 财政年份:
- 资助金额:
-- - 项目类别:
EXPRESSION OF ONCOGENES IN LYMPHOPROLIFERATIVE DISORDERS
淋巴增殖性疾病中癌基因的表达
- 批准号:
3808581 - 财政年份:
- 资助金额:
-- - 项目类别:
ANEUPLOIDY AND CELL CYCLE FRACTIONS IN BENIGN AND MALIGNANT TUMORS
良性和恶性肿瘤中的非整倍性和细胞周期分数
- 批准号:
3796581 - 财政年份:
- 资助金额:
-- - 项目类别:
ANEUPLOIDY AND CELL CYCLE FRACTIONS IN BENIGN AND MALIGNANT TUMORS
良性和恶性肿瘤中的非整倍性和细胞周期分数
- 批准号:
3774419 - 财政年份:
- 资助金额:
-- - 项目类别:
EXPRESSION OF ONCOGENES IN LYMPHOPROLIFERATIVE DISORDERS
淋巴增殖性疾病中癌基因的表达
- 批准号:
3796529 - 财政年份:
- 资助金额:
-- - 项目类别:
TIMP-1 EXPRESSION BY NORMAL LYMPHOCYTES AND IN LYMPHOID NEOPLASMS
正常淋巴细胞和淋巴肿瘤中的 TIMP-1 表达
- 批准号:
3796582 - 财政年份:
- 资助金额:
-- - 项目类别:
TIMP-1 EXPRESSION BY NORMAL LYMPHOCYTES AND IN LYMPHOID NEOPLASMS
正常淋巴细胞和淋巴肿瘤中的 TIMP-1 表达
- 批准号:
3774420 - 财政年份:
- 资助金额:
-- - 项目类别:
FLOW CYTOMETRIC ANALYSIS OF BENIGN AND MALIGNANT TUMORS
良性和恶性肿瘤的流式细胞术分析
- 批准号:
5201032 - 财政年份:
- 资助金额:
-- - 项目类别:
FLOW CYTOMETRIC ANALYSIS OF BENIGN AND MALIGNANT TUMORS
良性和恶性肿瘤的流式细胞术分析
- 批准号:
3752119 - 财政年份:
- 资助金额:
-- - 项目类别:
相似海外基金
GSK3 inhibition as an adjuvant therapy for Burkitt's lymphoma
GSK3 抑制作为伯基特淋巴瘤的辅助治疗
- 批准号:
8653055 - 财政年份:2014
- 资助金额:
-- - 项目类别:
The role of activation-induced cytidine deaminase (AID) mediated DNA damage in the pathogenesis of Burkitt's Lymphoma
活化诱导胞苷脱氨酶 (AID) 介导的 DNA 损伤在伯基特淋巴瘤发病机制中的作用
- 批准号:
258438392 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Research Fellowships
GSK3 inhibition as an adjuvant therapy for Burkitt's lymphoma
GSK3 抑制作为伯基特淋巴瘤的辅助治疗
- 批准号:
8788701 - 财政年份:2014
- 资助金额:
-- - 项目类别:
The interaction of Burkitt's lymphoma cofactors EBV and Plasmodium
伯基特淋巴瘤辅助因子 EBV 和疟原虫的相互作用
- 批准号:
8846480 - 财政年份:2012
- 资助金额:
-- - 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
- 批准号:
7289830 - 财政年份:2006
- 资助金额:
-- - 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
- 批准号:
7097879 - 财政年份:2006
- 资助金额:
-- - 项目类别:
REGULATION OF EBV TRANSCRIPTION IN BURKITT'S LYMPHOMA
伯基特淋巴瘤中 EBV 转录的调控
- 批准号:
7349162 - 财政年份:2006
- 资助金额:
-- - 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
- 批准号:
7684750 - 财政年份:2006
- 资助金额:
-- - 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
- 批准号:
7492826 - 财政年份:2006
- 资助金额:
-- - 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
- 批准号:
7935180 - 财政年份:2006
- 资助金额:
-- - 项目类别: